Clinical Trial Update: Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial compares the efficacy and safety of a new artificial tear formulation against Systane Ultra Multidose in adults with Dry Eye Disease; results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• New artificial tear formulation
• Systane Ultra Multidose

Snippet

Sponsor: Allergan | Conditions: Dry Eye Disease (DED) | Phase 3 | Status: COMPLETED | Results posted: 2024-06-26